Ascentage Pharma Group International filed a $200 million at-the-market (ATM) shelf on Form F-3ASR with the SEC on July 17, 2026, with Citigroup, Deutsche Bank and BTIG as sales agents, the first explicit US capital-raise architecture the company has staged since its January 2025 Nasdaq IPO. The shelf follows a fiscal year in which revenue of RMB 574.1 million (US$82.1 million) fell 41.5% from RMB 980.7 million in FY2024 because a one-time US$100 million Takeda option payment fell out of the comparable, while commercial pharmaceutical product sales in China continued to scale, rising to RMB 499.3 million (US$71.4 million) from RMB 260.8 million in FY2024, a 91.4% product-revenue print that is the load-bearing operational fact of the year. Net loss for FY2025 widened to RMB 1,243.0 million (US$177.7 million) from RMB 405.7 million in FY2024 as research and development spend grew 20.1% to RMB 1,137.4 million (US$162.7 million) and selling and distribution expense jumped 80.4% to RMB 353.6 million (US$50.6 million) on the second commercial launch in China.
We see the equity as a clinical-stage Chinese oncology platform that is now a commercial-stage Chinese oncology platform inside China but a clinical-stage story outside China, where the F-3ASR, the 767-employee global footprint, the appointment of a Chief Business Officer and a Chief Commercial Officer on August 2 2026, and four FDA-cleared registrational Phase 3 trials across the two lead assets collectively describe a US launch being staged for 2027-2028 rather than a near-term revenue event. The market is pricing the equity as an option on the global launch: shares of AAPG closed at $18.98 on the most recent session, the stock is down 60.8% from its 52-week high of $48.45, the market capitalization on a 370.67 million share base (the most recent disclosed count) is roughly $7.0 billion, and the average 9-analyst price target of $47.56 implies 150.6% upside. The next data point that tests this is the August 19 2026 2026 Six-Month Interim Results release, which is the first hard read on whether the Lisaftoclax launch that started in July 2025 is scaling into the US$38.2 billion global CLL/SLL market opportunity the company cites, and whether the $200 million ATM is sized to fund a US NDA filing rather than plug a China cash gap.